To transform the development of next-generation cancer therapies by providing more comprehensive molecular data about each patient’s tumor.
Elucidating Complex Biology in the Immuno-Oncology Era
Effectively predicting response to emerging precision oncology therapies — and developing new ones — requires a more comprehensive approach to tumor immunogenomics. By providing the most extensive molecular view of a patient’s tumor and characterizing its interplay with the immune system, the Personalis NeXT Platform™ enables the identification of next-generation composite biomarkers, with the ultimate goal of bringing the revolutionary potential of precision medicine to more cancer patients. Through partnerships with some of the world’s largest and most innovative biopharmaceutical companies, Personalis aids in the development of safer, more effective precision cancer therapies, immunotherapies, and personalized medicines.